

Statement of Principles

concerning

ACHILLES TENDINOPATHY AND BURSITIS

(Reasonable Hypothesis)

(No. 96 of 2015)

The Repatriation Medical Authority determines the following Statement of Principles under subsection 196B(2) of the *Veterans’ Entitlements Act 1986*.

Dated 21 August 2015

The Common Seal of the  
Repatriation Medical Authority  
was affixed to this instrument  
at the direction of:



Professor Nicholas Saunders AO

Chairperson

Contents

1 Name 3

2 Commencement 3

3 Authority 3

4 Revocation 3

5 Application 3

6 Definitions 3

7 Kind of injury, disease or death to which this Statement of Principles relates 3

8 Basis for determining the factors 4

9 Factors that must exist 4

10 Relationship to service 6

11 Factors referring to an injury or disease covered by another Statement of Principles 7

Schedule 1 - Dictionary 8

1 Definitions 8

1. Name

This is the Statement of Principles concerning *Achilles tendinopathy and bursitis**(Reasonable Hypothesis)*(No. of 2015).

1. Commencement

This instrument commences on **21 September 2015**.

1. Authority

This instrument is made under subsection 196B(2) of the *Veterans’ Entitlements Act 1986*.

1. Revocation

The Statement of Principles concerning Achilles tendinopathy and bursitis No. 37 of 2007 made under subsection 196B(2) of the VEA is revoked.

1. Application

This instrument applies to a claim to which section 120A of the VEA or section 338 of the *Military Rehabilitation and Compensation Act 2004* applies.

1. Definitions

The terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.

1. Kind of injury, disease or death to which this Statement of Principles relates
   1. This Statement of Principles is about Achilles tendinopathy and bursitis and death from Achilles tendinopathy and bursitis.

*Meaning of* ***Achilles tendinopathy and bursitis***

* 1. For the purposes of this Statement of Principles,
     1. Achilles tendinopathy means a condition characterised by painful inflammation associated with degeneration in the Achilles tendon, including degenerative tears of the Achilles tendon, or inflammation of the paratendinous tissues; and
     2. bursitis means inflammation and thickening of the deep retrocalcaneal bursa about the Achilles tendon; and
     3. excludes posterior adventitial heel bursitis.
  2. While Achilles tendinopathy and bursitis attracts ICD‑10‑AM code M76.6, in applying this Statement of Principles the meaning of Achilles tendinopathy and bursitis is that given in subsection (2).
  3. For subsection (3), a reference to an ICD‑10‑AM codeis a reference to the code assigned to a particular kind of injury or disease in *The International Statistical Classification of Diseases and Related Health Problems*, *Tenth Revision, Australian Modification* (ICD‑10‑AM), Ninth Edition, effective date of 1 July 2015, copyrighted by the Independent Hospital Pricing Authority, ISBN 978‑1‑76007‑020‑5.

*Death from* ***Achilles tendinopathy and bursitis***

* 1. For the purposes of this Statement of Principles, Achilles tendinopathy or bursitis,in relation to a person, includes death from a terminal event or condition that was contributed to by the person’s Achilles tendinopathy or bursitis.

Note: ***terminal event*** is defined in the Schedule 1 – Dictionary.

1. Basis for determining the factors

The Repatriation Medical Authority is of the view that there is sound medical‑scientific evidence that indicates that Achilles tendinopathy or bursitis and death from Achilles tendinopathy or bursitis can be related to relevant service rendered by veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, or members under the MRCA.

Note: ***relevant service*** is defined in the Schedule 1 – Dictionary.

1. Factors that must exist

At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting Achilles tendinopathy or bursitis or death from Achilles tendinopathy or bursitis with the circumstances of a person’s relevant service:

* 1. running or jogging an average of at least 30 kilometres per week for the four weeks before the clinical onset of Achilles tendinopathy or bursitis;
  2. undertaking weight bearing exercise involving repeated activity of the ankle joint of the affected leg, at a minimum intensity of five METs, for at least four hours per week for the four weeks before the clinical onset of Achilles tendinopathy or bursitis;

Note: ***MET*** is defined in the Schedule 1 - Dictionary.

* 1. increasing the frequency, duration or intensity of weight bearing activity involving the ankle joint of the affected leg by at least 100 percent, to a minimum intensity of five METs for at least two hours per day, within the seven days before the clinical onset of Achilles tendinopathy or bursitis;

Note: ***MET*** is defined in the Schedule 1 - Dictionary.

* 1. having a disease from the specified list of systemic arthritic diseases at the time of the clinical onset of Achilles tendinopathy or bursitis;

Note: ***specified list of systemic arthritic diseases*** is defined in the Schedule 1 - Dictionary.

* 1. having a significant biomechanical abnormality involving the affected foot or affected ankle at the time of the clinical onset of Achilles tendinopathy or bursitis;

Note: ***significant biomechanical abnormality*** is defined in the Schedule 1 – Dictionary.

* 1. undergoing a renal transplant within the ten years before the clinical onset of Achilles tendinopathy or bursitis;
  2. for Achilles tendinopathy only, undergoing treatment with fluoroquinolone antibiotics within the 14 days before the clinical onset of Achilles tendinopathy;
  3. being treated with a glucocorticoid drug as specified before the clinical onset of Achilles tendinopathy or bursitis;

Note: ***glucocorticoid drug as specified*** is defined in the Schedule 1 - Dictionary.

* 1. being obese at the time of the clinical onset of Achilles tendinopathy or bursitis;

Note: ***being obese*** is defined in the Schedule 1 - Dictionary.

* 1. having diabetes mellitusat the time ofthe clinical onset of Achilles tendinopathy or bursitis;
  2. being treated for at least four weeks with an aromatase inhibitor within the one year before the clinical onset of Achilles tendinopathy or bursitis;
  3. running or jogging an average of at least 30 kilometres per week for the four weeks before the clinical worsening of Achilles tendinopathy or bursitis;
  4. undertaking weight bearing exercise involving repeated activity of the ankle joint of the affected leg, at a minimum intensity of five METs, for at least four hours per week for the four weeks before the clinical worsening of Achilles tendinopathy or bursitis;

Note: ***MET*** is defined in the Schedule 1 - Dictionary.

* 1. increasing the frequency, duration or intensity of weight bearing activity involving the ankle joint of the affected leg by at least 100 percent, to a minimum intensity of five METs for at least two hours per day, within the seven days before the clinical worsening of Achilles tendinopathy or bursitis;

Note: ***MET*** is defined in the Schedule 1 - Dictionary.

* 1. having a disease from the specified list of systemic arthritic diseases at the time of the clinical worsening of Achilles tendinopathy or bursitis;

Note: ***specified list of systemic arthritic diseases*** is defined in the Schedule 1 - Dictionary.

* 1. having a significant biomechanical abnormality involving the affected foot or affected ankle at the time of the clinical worsening of Achilles tendinopathy or bursitis;

Note: ***significant biomechanical abnormality*** is defined in the Schedule 1 – Dictionary.

* 1. undergoing a renal transplant within the ten years before the clinical worsening of Achilles tendinopathy or bursitis;
  2. for Achilles tendinopathy only, undergoing treatment with fluoroquinolone antibiotics within the 14 days before the clinical worsening of Achilles tendinopathy;
  3. being treated with a glucocorticoid drug as specified before the clinical worsening of Achilles tendinopathy or bursitis;

Note: ***glucocorticoid drug as specified*** is defined in the Schedule 1 - Dictionary.

* 1. having a glucocorticoid injection into the Achilles tendon or in the region of the Achilles tendon, before the clinical worsening of Achilles tendinopathy or bursitis;
  2. being obese at the time of the clinical worsening of Achilles tendinopathy or bursitis;

Note: ***being obese*** is defined in the Schedule 1 - Dictionary.

* 1. having diabetes mellitusat the time ofthe clinical worsening of Achilles tendinopathy or bursitis;
  2. being treated for at least four weeks with an aromatase inhibitor within the one year before the clinical worsening of Achilles tendinopathy or bursitis;
  3. inability to obtain appropriate clinical management for Achilles tendinopathy or bursitis.

1. Relationship to service
   1. The existence in a person of any factor referred to in section 9 must be related to the relevant service rendered by the person.
   2. The factors set out in subsections 9(12) to 9(24) apply only to material contribution to, or aggravation of, Achilles tendinopathy or bursitis where the person’s Achilles tendinopathy or bursitis was suffered or contracted before or during (but did not arise out of) the person’s relevant service.
2. Factors referring to an injury or disease covered by another Statement of Principles

In this Statement of Principles:

* 1. if a factor referred to in section 9 applies in relation to a person; and
  2. that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(2) of the VEA;

then the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.

Schedule 1 - Dictionary

Note: See Section 6

1. Definitions
   1. In this instrument:
      1. ***Achilles tendinopathy and bursitis***—see subsection 7(2).
      2. ***being obese*** means having a Body Mass Index (BMI) of 30 or greater.

BMI = W/H2 and where:

W is the person's weight in kilograms; and

H is the person's height in metres.

* + 1. ***crystal-induced arthropathy*** means arthropathy resulting from the deposition of monosodium urate, calcium pyrophosphate dihydrate, calcium hydroxyapatite or calcium oxalate.
    2. ***glucocorticoid drug as specified*** means any of the corticosteroid drugs listed in the following table, in the specified combinations of administration, dose level and duration of treatment:

| **Drug or Class of Drugs** | **Mode\*** | **Dose** | **Minimum Duration of Treatment** | **Duration** |
| --- | --- | --- | --- | --- |
| prednisolone or  pharmacologically equivalent glucocorticoid | IV, IM, O | ≥ 0.5 grams over 6 months | 6 months | within the 3 years |
| ≥ 3 grams | NS | within the 5 years |
| ≥ 10 grams | NS | NS |

Abbreviations: IV = intravenous; IM = intramuscular; O = oral; NS = not specified.

* + 1. ***MET*** means a unit of measurement of the level of physical exertion. 1 MET = 3.5 ml of oxygen/kg of body weight per minute, or 1.0 kcal/kg of body weight per hour, or resting metabolic rate.
    2. **MRCA** means the *Military Rehabilitation and Compensation Act 2004*.
    3. ***relevant service*** means:

1. operational service under the VEA;
2. peacekeeping service under the VEA;
3. hazardous service under the VEA;
4. British nuclear test defence service under the VEA;
5. warlike service under the MRCA; or
6. non-warlike service under the MRCA.
   * 1. ***significant biomechanical abnormality*** means an abnormality that causes significant alteration of biomechanical forces through the ankle, such as would occur with pes planus or underpronation, decreased ankle or forefoot flexibility, forefoot varus, pes cavus or lateral ankle joint instability.
     2. ***specified list of systemic arthritic diseases*** means:
        1. ankylosing spondylitis;
        2. Behcet syndrome;
        3. gout, or another crystal-induced arthropathy;
        4. enteropathic spondyloarthropathy;
        5. psoriatic arthropathy;
        6. reactive arthritis;
        7. rheumatoid arthritis; or
        8. undifferentiated spondyloarthropathy.

Note: ***crystal-induced arthropathy*** is also defined in the Schedule 1 - Dictionary.

* + 1. ***terminal event*** means the proximate or ultimate cause of death and includes the following:
       1. pneumonia;
       2. respiratory failure;
       3. cardiac arrest;
       4. circulatory failure; or
       5. cessation of brain function.
    2. ***VEA*** means the *Veterans' Entitlements Act 1986*.